<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371070</url>
  </required_header>
  <id_info>
    <org_study_id>.1 259/2013BO1</org_study_id>
    <nct_id>NCT02371070</nct_id>
  </id_info>
  <brief_title>Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2</brief_title>
  <acronym>POCT-DOAC 2</acronym>
  <official_title>Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators study aims to test the correlation between the Hemochron Signature
      point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently
      approved direct oral anticoagulants (DOAC; rivaroxaban, apixaban and dabigatran) and to
      determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in
      real-life stroke patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect/Correlation of direct oral anticoagulants (DOAC) on Hemochron Signature point-of-care testing (POCT) result</measure>
    <time_frame>24 hours</time_frame>
    <description>DOAC concentrations determined by ultra-performance liquid chromatography-tandem mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of the Hemochron Signature POCT to rule out or detect relevant DOAC levels</measure>
    <time_frame>24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect/Correlation of DOAC on prothrombin time (PT), activated thromboplastin time (aPTT), anti-Xa activity and Hemoclot assay</measure>
    <time_frame>24h</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Anticoagulation With Direct Oral Anticoagulants</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples and citrated plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive stroke patients, who were newly started on oral anticoagulation with
        rivaroxaban, apixaban or dabigatran for secondary prevention of thromboembolic events.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stroke patients, who were newly started on oral anticoagulation with rivaroxaban,
             apixaban or dabigatran for secondary prevention of thromboembolic events

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Vitamin K antagonists or direct oral anticoagulants ≤ 14 days prior to study
             participation

          -  Low-molecular weight heparin ≤ 24 hours

          -  Unfractionated heparin ≤ 12 hours

          -  Abnormal coagulation values at baseline (Quick &lt; 70% or activated thromboplastin time
             (aPTT) &gt; 40sec.)

          -  History of coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Poli, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

